Terminated NA INTERVENTIONAL 1-arm NCT05199961

Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel

Sponsor: Novartis

Conditions Lymphoma, Large B-Cell, Diffuse

Updated 5 times since 2022 Last updated: May 11, 2023 Started: Jan 25, 2022 Primary completion: Sep 13, 2022 Completion: Sep 13, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor requested early termination

Other terminated trials from Novartis

See all terminations from Novartis

Other Lymphoma, Large B-Cell, Diffuse trials with similar outcome

Browse all Lymphoma, Large B-Cell, Diffuse trials

A NA clinical study on Lymphoma, Large B-Cell, Diffuse, this trial is terminated or withdrawn. The trial is conducted by Novartis and has accumulated 5 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jun 2023 — Jul 2024 [monthly]

Terminated NA

Status: Recruiting → Terminated
May 2022 — Jun 2023 [monthly]

Recruiting NA
Feb 2022 — May 2022 [monthly]

Recruiting NA

First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Ohio State University Comprehensive Cancer Center
Pack Health

Data source: Pack Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Columbus, United States